Anti-MEK1 (phospho S298) antibody (ab5613)

Overview

  • Product nameAnti-MEK1 (phospho S298) antibody
    See all MEK1 primary antibodies
  • Description
    Rabbit polyclonal to MEK1 (phospho S298)
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    The antiserum was produced against a chemically synthesized phosphopeptide derived from a region of human MEK 1 that contains serine 298.

  • Positive control
    • NIH3T3 cells +/- PDGF, A431 +/- EGF, PC12 +/- NGF.

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage bufferPreservative: 0.05% Sodium Azide
    Constituents: PBS, 1mg/ml BSA (IgG, protease free). pH 7.3
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Purification notesThe antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated MEK 1. The final product is generated by affinity chromatography using a MEK 1 derived peptide that is phosphorylated at serine 298.
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab5613 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 0.1 - 1 µg/ml. Detects a band of approximately 50 kDa.

Target

  • FunctionCatalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP kinases.
  • Tissue specificityWidely expressed, with extremely low levels in brain.
  • Involvement in diseaseDefects in MAP2K1 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
  • Sequence similaritiesBelongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    Phosphorylation on Ser/Thr by MAP kinase kinase kinases (RAF or MEKK1) regulates positively the kinase activity.
    Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
  • Information by UniProt
  • Database links
  • Alternative names
    • Dual specificity mitogen activated protein kinase kinase 1 antibody
    • Dual specificity mitogen-activated protein kinase kinase 1 antibody
    • ERK activator kinase 1 antibody
    • MAP kinase kinase 1 antibody
    • MAP kinase/Erk kinase 1 antibody
    • MAP2K1 antibody
    • MAPK/ERK kinase 1 antibody
    • MAPKK 1 antibody
    • MAPKK1 antibody
    • MEK 1 antibody
    • Mek1 antibody
    • MEKK1 antibody
    • Mitogen activated protein kinase kinase 1 antibody
    • MKK 1 antibody
    • MKK1 antibody
    • MP2K1_HUMAN antibody
    • PRKMK1 antibody
    • Protein kinase mitogen activated kinase 1 (MAP kinase kinase 1) antibody
    • Protein kinase mitogen activated, kinase 1 antibody
    see all

Anti-MEK1 (phospho S298) antibody images

  • Peptide Competition: Extracts prepared from NIH3T3 cells treated with PDGF were resolved by SDS-PAGE on a 10% Tris-glycine gel and transferred to PVDF. Membranes were blocked with a 5% BSA-TBST buffer overnight at 4oC, then were incubated with 0.50 µg/mL ab5613 antibody for two hours at room temperature, following prior incubation with: the phosphopeptide immunogen (1), the nonphosphopeptide corresponding to the immunogen (2), a generic phosphoserine containing peptide (3), or, no peptide (4). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and signals were detected using the Tropix WesternStar method. Phosphatase Stripping: Extracts prepared from NIH3T3 cells not treated or treated (+PDGF) with PDGF were resolved by SDS-PAGE on a 10% Tris-glycine gel and transferred to PVDF. The membrane was either treated (lane 5) or not treated (lanes 6, 7) with lambda phosphatase, then incubated with 0.50 µg/mL ab5613 antibody for two hours at room temperature. After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and signals were detected using the Tropix WesternStar method. The data show that only the peptide corresponding to ab5613 blocks the antibody signal, demonstrating the specificity of the antibody. The data also show that phosphatase stripping eliminates the signal, verifying that the antibody is phospho-specific.

References for Anti-MEK1 (phospho S298) antibody (ab5613)

ab5613 has not yet been referenced specifically in any publications.

Product Wall

Thank you for your enquiry. I am able to provide you with the following information; for some of the antibodies that you are interested in, immunogen information is considered to be proprietary. Ab7948: The sequence is as follows: IFEETARFQPGYRS ...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"